To include your compound in the COVID-19 Resource Center, submit it here.

Moxifloxacin regimens miss Phase III endpoint

The not-for-profit Global Alliance for TB Drug Development said use of moxifloxacin in combination regimens did not

Read the full 176 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE